Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 51, 2021 - Issue 10
177
Views
2
CrossRef citations to date
0
Altmetric
Clinical Pharmacokinetics and Metabolism

The in vivo disposition of subcutaneous injected 14C-razuprotafib (14C-AKB-9778), a sulphamic acid phosphatase inhibitor, in nonclinical species and human

ORCID Icon, , &
Pages 1132-1145 | Received 22 Jun 2021, Accepted 21 Aug 2021, Published online: 01 Sep 2021
 

Abstract

  1. The disposition of radioactivity following subcutaneous 14C-razuprotafib, a Tie2 activator, was explored in multiple species.

  2. The absorption and clearance of razuprotafib and total radioactivity in human plasma are rapid and pharmacokinetics support razuprotafib as primary circulating component. Radioactivity is distributed greater to human plasma than whole blood (B:P = 0.36).

  3. In pigmented rats, radioactivity distributes to whole-body tissues rapidly and, within 24 h, is localised to elimination pathway end organs and injection site.

  4. Overall recovery of radioactivity across species is >93%, with the majority recovered within 24–48 h, and >80% in faeces.

  5. The CYP2C8 enzyme contributes significantly to razuprotafib metabolism.

  6. A hydrolysis product of razuprotafib (m/z 380) is the main component in rat plasma at 2 h (49% peak area radioactivity), while razuprotafib (m/z 585) is the main component in plasma for dog (58%), monkey (99.3%), and human (100%).

  7. Razuprotafib is present in dog, monkey, and human faeces, with the greatest percentage of radioactivity as metabolites. The major metabolite (>25%) in monkey and human, m/z 633, is an S-methylated oxidised derivative of razuprotafib and is localised in faeces.

  8. Overall disposition of 14C-razuprotafib in human is best modelled by monkey over lower order species.

Disclosure statement

The authors report no declarations of interest.

Correction Statement

This article has been republished with minor changes. These changes do not impact the academic content of the article.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.